nodes	percent_of_prediction	percent_of_DWPC	metapath
Degarelix—Stiffness—Hydrochlorothiazide—nephrolithiasis	0.0763	0.0779	CcSEcCtD
Degarelix—Joint swelling—Hydrochlorothiazide—nephrolithiasis	0.0592	0.0604	CcSEcCtD
Degarelix—Musculoskeletal stiffness—Hydrochlorothiazide—nephrolithiasis	0.0324	0.033	CcSEcCtD
Degarelix—Nocturia—Hydrochlorothiazide—nephrolithiasis	0.0313	0.0319	CcSEcCtD
Degarelix—Musculoskeletal pain—Hydrochlorothiazide—nephrolithiasis	0.0294	0.03	CcSEcCtD
Degarelix—Diabetes mellitus—Hydrochlorothiazide—nephrolithiasis	0.0242	0.0247	CcSEcCtD
Degarelix—Swelling—Hydrochlorothiazide—nephrolithiasis	0.0239	0.0244	CcSEcCtD
Degarelix—Libido decreased—Hydrochlorothiazide—nephrolithiasis	0.0227	0.0232	CcSEcCtD
Degarelix—Hot flush—Hydrochlorothiazide—nephrolithiasis	0.0225	0.023	CcSEcCtD
Degarelix—Menopausal symptoms—Hydrochlorothiazide—nephrolithiasis	0.0223	0.0228	CcSEcCtD
Degarelix—Atrial fibrillation—Hydrochlorothiazide—nephrolithiasis	0.0222	0.0227	CcSEcCtD
Degarelix—Renal impairment—Hydrochlorothiazide—nephrolithiasis	0.0221	0.0226	CcSEcCtD
Degarelix—Disturbance in sexual arousal—Hydrochlorothiazide—nephrolithiasis	0.0209	0.0213	CcSEcCtD
Degarelix—Breast disorder—Hydrochlorothiazide—nephrolithiasis	0.019	0.0194	CcSEcCtD
Degarelix—Muscular weakness—Hydrochlorothiazide—nephrolithiasis	0.0186	0.019	CcSEcCtD
Degarelix—Dysuria—Hydrochlorothiazide—nephrolithiasis	0.017	0.0174	CcSEcCtD
Degarelix—Pollakiuria—Hydrochlorothiazide—nephrolithiasis	0.0168	0.0172	CcSEcCtD
Degarelix—Erectile dysfunction—Hydrochlorothiazide—nephrolithiasis	0.0168	0.0171	CcSEcCtD
Degarelix—Weight increased—Hydrochlorothiazide—nephrolithiasis	0.0166	0.0169	CcSEcCtD
Degarelix—Hyperglycaemia—Hydrochlorothiazide—nephrolithiasis	0.0164	0.0168	CcSEcCtD
Degarelix—Acute coronary syndrome—Hydrochlorothiazide—nephrolithiasis	0.016	0.0163	CcSEcCtD
Degarelix—Renal failure—Hydrochlorothiazide—nephrolithiasis	0.016	0.0163	CcSEcCtD
Degarelix—Myocardial infarction—Hydrochlorothiazide—nephrolithiasis	0.0159	0.0162	CcSEcCtD
Degarelix—Urinary tract infection—Hydrochlorothiazide—nephrolithiasis	0.0158	0.0161	CcSEcCtD
Degarelix—Hypoaesthesia—Hydrochlorothiazide—nephrolithiasis	0.0145	0.0148	CcSEcCtD
Degarelix—Oedema peripheral—Hydrochlorothiazide—nephrolithiasis	0.0144	0.0146	CcSEcCtD
Degarelix—Arrhythmia—Hydrochlorothiazide—nephrolithiasis	0.013	0.0133	CcSEcCtD
Degarelix—Alopecia—Hydrochlorothiazide—nephrolithiasis	0.0129	0.0131	CcSEcCtD
Degarelix—Erythema—Hydrochlorothiazide—nephrolithiasis	0.0127	0.0129	CcSEcCtD
Degarelix—Back pain—Hydrochlorothiazide—nephrolithiasis	0.0123	0.0125	CcSEcCtD
Degarelix—Muscle spasms—Hydrochlorothiazide—nephrolithiasis	0.0122	0.0124	CcSEcCtD
Degarelix—Vision blurred—Hydrochlorothiazide—nephrolithiasis	0.012	0.0122	CcSEcCtD
Degarelix—Ill-defined disorder—Hydrochlorothiazide—nephrolithiasis	0.0118	0.012	CcSEcCtD
Degarelix—Anaemia—Hydrochlorothiazide—nephrolithiasis	0.0117	0.012	CcSEcCtD
Degarelix—Malaise—Hydrochlorothiazide—nephrolithiasis	0.0114	0.0117	CcSEcCtD
Degarelix—Palpitations—Hydrochlorothiazide—nephrolithiasis	0.0112	0.0114	CcSEcCtD
Degarelix—Arthralgia—Hydrochlorothiazide—nephrolithiasis	0.0108	0.011	CcSEcCtD
Degarelix—Discomfort—Hydrochlorothiazide—nephrolithiasis	0.0107	0.0109	CcSEcCtD
Degarelix—Dry mouth—Hydrochlorothiazide—nephrolithiasis	0.0106	0.0108	CcSEcCtD
Degarelix—Anaphylactic shock—Hydrochlorothiazide—nephrolithiasis	0.0104	0.0106	CcSEcCtD
Degarelix—Hyperhidrosis—Hydrochlorothiazide—nephrolithiasis	0.01	0.0102	CcSEcCtD
Degarelix—Hypotension—Hydrochlorothiazide—nephrolithiasis	0.00968	0.00987	CcSEcCtD
Degarelix—Musculoskeletal discomfort—Hydrochlorothiazide—nephrolithiasis	0.00943	0.00962	CcSEcCtD
Degarelix—Insomnia—Hydrochlorothiazide—nephrolithiasis	0.00936	0.00955	CcSEcCtD
Degarelix—Dyspnoea—Hydrochlorothiazide—nephrolithiasis	0.00923	0.00942	CcSEcCtD
Degarelix—Decreased appetite—Hydrochlorothiazide—nephrolithiasis	0.009	0.00918	CcSEcCtD
Degarelix—Fatigue—Hydrochlorothiazide—nephrolithiasis	0.00893	0.00911	CcSEcCtD
Degarelix—Pain—Hydrochlorothiazide—nephrolithiasis	0.00885	0.00903	CcSEcCtD
Degarelix—Constipation—Hydrochlorothiazide—nephrolithiasis	0.00885	0.00903	CcSEcCtD
Degarelix—Feeling abnormal—Hydrochlorothiazide—nephrolithiasis	0.00853	0.0087	CcSEcCtD
Degarelix—Gastrointestinal pain—Hydrochlorothiazide—nephrolithiasis	0.00847	0.00864	CcSEcCtD
Degarelix—Urticaria—Hydrochlorothiazide—nephrolithiasis	0.00823	0.00839	CcSEcCtD
Degarelix—Body temperature increased—Hydrochlorothiazide—nephrolithiasis	0.00819	0.00835	CcSEcCtD
Degarelix—Abdominal pain—Hydrochlorothiazide—nephrolithiasis	0.00819	0.00835	CcSEcCtD
Degarelix—Hypersensitivity—Hydrochlorothiazide—nephrolithiasis	0.00763	0.00778	CcSEcCtD
Degarelix—Asthenia—Hydrochlorothiazide—nephrolithiasis	0.00743	0.00758	CcSEcCtD
Degarelix—Pruritus—Hydrochlorothiazide—nephrolithiasis	0.00733	0.00747	CcSEcCtD
Degarelix—Diarrhoea—Hydrochlorothiazide—nephrolithiasis	0.00708	0.00723	CcSEcCtD
Degarelix—Dizziness—Hydrochlorothiazide—nephrolithiasis	0.00685	0.00698	CcSEcCtD
Degarelix—Vomiting—Hydrochlorothiazide—nephrolithiasis	0.00658	0.00672	CcSEcCtD
Degarelix—Rash—Hydrochlorothiazide—nephrolithiasis	0.00653	0.00666	CcSEcCtD
Degarelix—Dermatitis—Hydrochlorothiazide—nephrolithiasis	0.00652	0.00665	CcSEcCtD
Degarelix—Headache—Hydrochlorothiazide—nephrolithiasis	0.00649	0.00662	CcSEcCtD
Degarelix—Nausea—Hydrochlorothiazide—nephrolithiasis	0.00615	0.00627	CcSEcCtD
Degarelix—GNRHR—GPCRs, Other—CHRM3—nephrolithiasis	0.00286	0.145	CbGpPWpGaD
Degarelix—GNRHR—G alpha (q) signalling events—DGKH—nephrolithiasis	0.00222	0.112	CbGpPWpGaD
Degarelix—GNRHR—Gastrin-CREB signalling pathway via PKC and MAPK—DGKH—nephrolithiasis	0.00199	0.101	CbGpPWpGaD
Degarelix—GNRHR—G alpha (q) signalling events—CHRM3—nephrolithiasis	0.00161	0.0813	CbGpPWpGaD
Degarelix—GNRHR—Gastrin-CREB signalling pathway via PKC and MAPK—CHRM3—nephrolithiasis	0.00144	0.0727	CbGpPWpGaD
Degarelix—GNRHR—Class A/1 (Rhodopsin-like receptors)—CHRM3—nephrolithiasis	0.00106	0.0539	CbGpPWpGaD
Degarelix—GNRHR—GPCR downstream signaling—RGS14—nephrolithiasis	0.000937	0.0475	CbGpPWpGaD
Degarelix—GNRHR—Signaling by GPCR—RGS14—nephrolithiasis	0.000851	0.0431	CbGpPWpGaD
Degarelix—GNRHR—GPCR ligand binding—CHRM3—nephrolithiasis	0.00081	0.041	CbGpPWpGaD
Degarelix—GNRHR—GPCR ligand binding—PTH—nephrolithiasis	0.000741	0.0375	CbGpPWpGaD
Degarelix—GNRHR—GPCR downstream signaling—DGKH—nephrolithiasis	0.000633	0.0321	CbGpPWpGaD
Degarelix—GNRHR—Signaling Pathways—ADCY10—nephrolithiasis	0.000591	0.0299	CbGpPWpGaD
Degarelix—GNRHR—Signaling by GPCR—DGKH—nephrolithiasis	0.000575	0.0291	CbGpPWpGaD
Degarelix—GNRHR—Signaling Pathways—RGS14—nephrolithiasis	0.000503	0.0255	CbGpPWpGaD
Degarelix—GNRHR—GPCR downstream signaling—CHRM3—nephrolithiasis	0.000458	0.0232	CbGpPWpGaD
Degarelix—GNRHR—GPCR downstream signaling—PTH—nephrolithiasis	0.000419	0.0212	CbGpPWpGaD
Degarelix—GNRHR—Signaling by GPCR—CHRM3—nephrolithiasis	0.000416	0.021	CbGpPWpGaD
Degarelix—GNRHR—Signaling by GPCR—PTH—nephrolithiasis	0.00038	0.0193	CbGpPWpGaD
Degarelix—GNRHR—Signaling Pathways—ATP6V0A4—nephrolithiasis	0.00034	0.0172	CbGpPWpGaD
Degarelix—GNRHR—Signaling Pathways—DGKH—nephrolithiasis	0.00034	0.0172	CbGpPWpGaD
Degarelix—GNRHR—Signaling Pathways—CHRM3—nephrolithiasis	0.000246	0.0124	CbGpPWpGaD
Degarelix—GNRHR—Signaling Pathways—PTH—nephrolithiasis	0.000225	0.0114	CbGpPWpGaD
Degarelix—GNRHR—Signaling Pathways—SPP1—nephrolithiasis	0.000113	0.00571	CbGpPWpGaD
